Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New York City. Founded in 1849, Pfizer discovers, develops and manufactures ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...

Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo ...

Returns for PFE stock were 67% in 2021, -10% in 2022, and -41% in 2023. In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, is considerably less volatile.

The Zacks Consensus Estimate for PFE’s 2025 sales implies a year-over-year decrease of 0.6% and 1%, respectively. EPS estimates for both 2025 and 2026 have risen over the past 60 days.

A few weeks back, we discussed that Pfizer’s (NYSE: PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has ...